Abstract
Cardiometabolic syndrome is a mixture of interrelated risk factors predisposing individuals to elevated risk of atherosclerotic cardiovascular disease and type 2 diabetes mellitus. Nuclear receptors, specifically peroxisome proliferator-activated receptors (PPARs), were identified to play a pivotal role in the regulation of metabolic homeostasis. However, with rosiglitazone currently under intense scrutiny great concerns have arisen regarding the safety of the thiazolidinedione PPAR-γ agonist family as a whole. This review discusses the current concern with PPAR-γ agonists by exploring if PPARs can still be considered worth pursuing as a viable target for cardiovascular diseases. We examine current research focusing on identifying ligands that are dual and pan-PPAR agonists, selective PPAR-γ modulators, PPAR-β/δ agonists and that are of natural origin.
| Original language | English |
|---|---|
| Pages (from-to) | 241-247 |
| Number of pages | 7 |
| Journal | Current Molecular Pharmacology |
| Volume | 5 |
| Issue number | 2 |
| Publication status | Published - 2012 |
Keywords
- cardiometabolic syndrome
- diabetes
- herbs
- plant products
- therapeutic use
